Streetbeat News

Stock Prices

EEX

Emerald Holding's stock price declined following the announcement of Q4 sales that fell short of expectations.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 7:09 pm

RNA

Avidity Biosciences shares surged following the announcement of a $400 million oversubscribed private placement, indicating strong investor interest.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 7:05 pm

PFE

Pfizer Inc (NYSE:PFE) announced that its Abrysvo vaccine for respiratory syncytial virus (RSV) in adults 60 and older maintained efficacy through a second RSV season, according to Phase 3 trial data. The vaccine showed 77.8% efficacy against severe RSV after the second season, with overall efficacy across both seasons at 81.5%. No new adverse events were reported in the second season. Abrysvo, approved by the FDA for preventing infection in infants, generated $890 million in sales in fiscal year 2023. PFE shares dropped 1.07% to $26.76.

Portfolio Pulse from Vandana Singh

February 29, 2024 | 7:04 pm

XLMUSD

Stellar (CRYPTO: XLM) has seen a 4.52% increase in price over the last 24 hours, reaching $0.12. This is part of a positive trend over the past week, with a 7.0% gain. The coin's all-time high is $0.88. Trading volume has surged by 152.0% over the past week, and the circulating supply has slightly increased to over 28.50 billion, representing approximately 56.99% of its max supply. Stellar's market cap ranking is now #37 at $3.55 billion.

Portfolio Pulse from Benzinga Insights

February 29, 2024 | 7:03 pm

RVNC

Revance Therapeutics' stock price increased following the announcement of their Q4 financial results, which exceeded expectations.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 7:03 pm

HBARUSD

Hedera (CRYPTO: HBAR) has seen a price increase of 6.1% in the last 24 hours, reaching $0.12, despite a 1.0% loss over the past week. Its all-time high is $0.57. Trading volume has decreased by 13.0%, and the circulating supply has slightly decreased to 33.69 billion, which is 67.37% of its max supply. HBAR's market cap ranks it #34 at $3.88 billion.

Portfolio Pulse from Benzinga Insights

February 29, 2024 | 7:03 pm

ETSY

Significant options trading activity on Etsy (NASDAQ:ETSY) indicates a mixed sentiment among big-money investors, with a lean towards bearishness. Benzinga's options scanner revealed 9 unusual trades, showing a split sentiment of 44% bullish and 55% bearish. The trades focus on a price band between $60.0 and $90.0 for Etsy. Analysts have varying views on Etsy, with target prices ranging from $64 to $95. The company, a major e-commerce marketplace, reported a consolidated gross merchandise volume of $13.2 billion in 2023.

Portfolio Pulse from Benzinga Insights

February 29, 2024 | 7:02 pm

MIRM

Mirum Pharmaceuticals (NASDAQ:MIRM) has received mixed analyst ratings over the last quarter, with a shift towards a more cautious outlook. The average 12-month price target has been adjusted to $55.25, down from $69.00, indicating a 19.93% decrease. Analysts from firms like Cantor Fitzgerald, JMP Securities, Raymond James, and HC Wainwright & Co. have provided updates, with some maintaining their ratings and others lowering their price targets. Mirum Pharmaceuticals, a biopharmaceutical company, focuses on therapies for rare diseases and has shown significant revenue growth and a strong market presence, despite challenges in debt management and return on equity.

Portfolio Pulse from Benzinga Insights

February 29, 2024 | 7:02 pm

ATOMUSD

Cosmos Hub (CRYPTO: ATOM) has seen a significant price increase of 5.08% in the last 24 hours, reaching $11.73, with a weekly gain of over 17% from $9.92. The cryptocurrency's trading volume surged by 54% over the week, while its circulating supply rose by 0.46% to 388.48 million. Currently, ATOM's market cap ranks it 24th at $4.53 billion.

Portfolio Pulse from Benzinga Insights

February 29, 2024 | 7:01 pm

STEM

Stem (NYSE:STEM) has received mixed analyst ratings over the past three months, with a shift towards a more cautious outlook. The average 12-month price target for STEM has been lowered to $4.05, indicating a 26.36% decrease from the previous target of $5.50. Analysts from firms including Susquehanna, Piper Sandler, BMO Capital, Goldman Sachs, and Morgan Stanley have all adjusted their ratings and price targets downwards, reflecting concerns over market conditions and company performance. Despite this, Stem's financials show a positive revenue trend with a growth rate of 34.41% as of September 30, 2023, but challenges in net margin, ROE, ROA, and a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

February 29, 2024 | 7:00 pm